Drug Type Small molecule drug |
Synonyms Glucoprime, GLYC-101, MG-3601 + [3] |
Target |
Action modulators, stimulants |
Mechanism TLR2 modulators(Toll like receptor 2 modulators), Macrophages stimulants |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic venous insufficiency | Phase 3 | United States | 28 Jan 2025 | |
Varicose Ulcer | Phase 3 | United States | 28 Jan 2025 | |
Wounds and Injuries | Phase 3 | United States | 28 Jan 2025 |
Phase 2 | 82 | tzoxhyybyq(etsssykcum) = vnmmndarzx shvchiezpl (vxdosewqhp ) View more | Positive | 03 Jul 2023 | |||
Placebo gel | tzoxhyybyq(etsssykcum) = yxakhmlbwk shvchiezpl (vxdosewqhp ) View more | ||||||
Phase 1/2 | 12 | (GLYC-101 Active Retro-auricular Site (1 Per Participant)) | snebretegw(nxadexprlk) = ilnkesdxsd nzliqkqxat (thhltljztr, hebmzkmypw - doqmoknofq) View more | - | 25 Jul 2011 | ||
Placebo (Placebo Retro-auricular Site (1 Per Participant)) | snebretegw(nxadexprlk) = iuggjttrje nzliqkqxat (thhltljztr, glqpelagww - lbyzfospkn) View more |